|The following article features coverage from the European Hematology Association (EHA) 2021 Virtual Congress. Click here to read more of Hematology Advisor‘s conference coverage.|
Among heavily pretreated patients with relapsed/refractory multiple myeloma (MM), iberdomide-based regimens appear to yield promising safety and efficacy outcomes, supporting further study of this therapy, according to research presented at the European Hematology Association (EHA) 2021 Virtual Congress.
Iberdomide, a novel, orally administered cereblon E3 ligase modulator, has shown synergistic effects with both proteasome inhibitors and CD38-targeting monoclonal antibodies, both in preclinical and clinical study. The ongoing phase 1/2 CC-220-MM-001 trial (ClinicalTrials.gov Identifier: NCT02773030) is evaluating the optimal dose and safety of iberdomide-based regimens among patients with relapsed/refractory MM.
In this presentation, researchers reported CC-220-MM-001 data from 3 of the study’s cohorts: iberdomide, daratumumab, and dexamethasone (IberDd); iberdomide, bortezomib, and dexamethasone (IberVd); and iberdomide, bortezomib, and carfilzomib (IberKd).
At the time of EHA 2021, 43 patients had been enrolled and received IberDd, 25 patients had received IberVd, and 9 patients had received IberKd; the average numbers of prior therapies were 4 (range, 2-13), 5.5 (range, 1-14), and 6 (range, 2-8), respectively. All patients were refractory to their last line of therapy and had been diagnosed at least 6.5 years prior to enrollment.
At analysis, 22, 6, and 5 patients remained on treatment in the IberDd, IberVd, and IberKd groups, respectively, and the median number of treatment cycles were 4, 6, and 5, respectively.
In the IberDd, IberVd, and IberKd cohorts, the overall response rates were 45.9%, 56%, and 50%, respectively. The median times to response were 4.1, 3.6, and 4.1 weeks, respectively.
The median duration of response was 35.7 weeks with IberVd compared with not reached in patients who received IberDd and IberKd.
Common hematologic grade 3 or worse treatment-emergent adverse events (AEs) were neutropenia (66.6%) and anemia (20.5%) in the IberDd group; neutropenia (28%) and thrombocytopenia (24%) in the IberVd group; and neutropenia (33.3%) in the IberKd group.
The recommended phase 2 dose in the IberDd group was 1.6 mg; evaluation of this is ongoing in the other groups.
Disclosure: The presenter declared affiliations with Bristol Meyers Squibb and Celgene, a Bristol Myers Squibb Company.
Read more of Cancer Therapy Advisor’s coverage of the EHA 2021 Virtual Congress by visiting the conference page.
Lonial S, Richardson PG, Popat R, et al. Iberdomide (iber) in combination with dexamethasone (dex) and daratumumab (dara), bortezomib (bort), or carfilzomib (cfz) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Paper presented at: European Hematology Association 2021 Virtual Congress; June 2021; Abstract S187.
This article originally appeared on Cancer Therapy Advisor